Nope, Only the wealthy countries will be able to afford this. Not withstanding the likelihood that we will not be able to scale production enough to treat everyone. The actual production costs will be non trivial and probably price the treatment out of the range of many (even without amortizing R&D costs).
As a LT shareholder that has risked their money supporting this without any return for close to a decade I fully expect to reap the rewards if we are successful.
Mesoblast's primary consideration is to maximize the return to their investors. That is the system we live in.
Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L, page-354
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
0.045(3.33%) |
Mkt cap ! $1.592B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.42 | $1.33 | $3.802M | 2.753M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 23940 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 22571 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |